Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 11, 2019Journal of Diabetes

Teriparatide (recombinant human parathyroid hormone 1‐34) increases foot bone remodeling in diabetic chronic Charcot neuroarthropathy: a randomized double‐blind placebo‐controlled study

View Full Paper
Ask AI
Bookmark
Share

Authors

ARAshu RastogiAHAbhishek HajelaMPMahesh Prakash

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Rastogi et al. (2019) studied this question.

synapsesocial.com/papers/6a973f178bc05dff469bb4fchttps://doi.org/10.1111/1753-0407.12902
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Calcaneal Quantitative Ultrasound as a Determinant of Bone Health Status: What Properties of Bone Does It Reflect?2013 · 167 citations
  2. 2Teriparatide Increases Bone Formation in Modeling and Remodeling Osteons and Enhances IGF-II Immunoreactivity in Postmenopausal Women With Osteoporosis2006 · 231 citations
  3. 3Increases in BMD Correlate With Improvements in Bone Microarchitecture With Teriparatide Treatment in Postmenopausal Women With Osteoporosis2007 · 78 citations
  4. 4Charcot foot syndrome2015 · 81 citations
  5. 5Teriparatide for osteoporosis: importance of the full course2016 · 204 citations